Last reviewed · How we verify

Apidra — Competitive Intelligence Brief

Apidra (Apidra) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Metabolic.

marketed Insulin receptor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Apidra (Apidra) — Kinderkrankenhaus auf der Bult.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Apidra TARGET Apidra Kinderkrankenhaus auf der Bult marketed Insulin receptor
Tresiba INSULIN DEGLUDEC Novo Nordisk marketed Insulin Analog [EPC] Insulin receptor 2015-01-01
Levemir INSULIN DETEMIR Novo Nordisk marketed Insulin Analog [EPC] Insulin receptor 2005-01-01
Apidra INSULIN GLULISINE Sanofi marketed Insulin Analog [EPC] Insulin receptor 2004-01-01
Novolog INSULIN ASPART Novo Nordisk marketed Insulin Analog [EPC] Insulin receptor 2000-01-01
Lantus INSULIN GLARGINE Sanofi marketed Insulin Analog [EPC] Insulin receptor 2000-01-01
Humalog INSULIN LISPRO Eli Lilly marketed Insulin Analog [EPC] Insulin receptor 1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Apidra — Competitive Intelligence Brief. https://druglandscape.com/ci/apidra. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: